OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
SEELQ
Seelos Therapeutics, Inc.
Common Stock
Seelos Therapeutics, Inc.
300 Park Avenue
2nd Floor
New York, NY 10022
Last Verified 10/2024
Business Description
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the ...
More
Financial Reporting
Reporting Status
U.S. Reporting: SEC Reporting
Audited Financials
Audited
Latest Report
CIK
0001017491
Fiscal Year End
12/31
Company Officers & Contacts
Raj Mehra
CEO
Michael Joseph Golembiewski
CFO
Board of Directors
Margaret Dalesandro
Independent Director, Audit Committee Member, Nominating Committee Member
Brian Lian
Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
Richard W. Pascoe
Independent Director, Audit Committee Member, Compensation Committee Member
Other Company Insiders
None
Service Providers
Accounting/Auditing Firm
KPMG LLP - New York, New York, (USA)345 Park Avenue
New York, NY 10154-0102
Securities Counsel
Sullivan & Worcester LLP1633 Broadway
New York, NY 10019
Profile Data
SIC - Industry Classification
2834 - Pharmaceutical preparations
Incorporation Information
NV, US, 1987
Employees
8 as of 08/21/2024
Shell
No
Products and Services
we are a clinical-stage biopharmaceutical company.
Company Facilities
We do not own any property, we lease an office in New York City
Company Notes
Formerly=Apricus Biosciences, Inc. until 1-2019
Formerly=NexMed, Inc. until 9-2010
Note=11-97 company is in the development stage
Formerly=BioElectric, Inc. until 10-95
This market serves broker-dealer pricing and investor best execution needs. Quotations in Expert Market securities are restricted from public viewing.
Company is not current in its reporting obligations under Section 13 or 15(d) of the Exchange Act.
The company’s transfer agent has verified its outstanding shares directly to OTC Markets.
This company is currently in Bankruptcy or reorganization proceedings.
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.
Loading...
Symbol
OTCM
Last
51.15
Change
0.15 (0.29%)
Bid
N/A
Ask
N/A
Volume
13900
Time
15:59
